Featured Research

from universities, journals, and other organizations

Contrast Agent Allows Quicker, More Thorough MRI Screening Of Living Liver Donors Before Surgery

Date:
August 5, 2005
Source:
American Roentgen Ray Society
Summary:
A single dose of the contrast agent gadobenate dimeglumine can help liver donors avoid multiple MRI examinations during the screening process, cutting down on time and cost without compromising accuracy, say researchers from the Yonsei University College of Medicine in Seoul, Korea.

A single dose of the contrast agent gadobenate dimeglumine can help liver donorsavoid multiple MRI examinations during the screening process, cutting down ontime and cost without compromising accuracy, say researchers from the Yonsei UniversityCollege of Medicine in Seoul, Korea.

For the study, 11 potential liver donors underwent MRI examinations after asingle dose of gadobenate dimeglumine in order to screen them for donor adequacy.The researchers were able to find anatomical abnormalities in six of the patientsthat potentially could have affected either the selection or the surgery process.The MRI results were all corroborated at surgery.

"Preoperative imaging is crucial for both the selection of potential livingliver donors and the planning of surgery because it reveals the exact anatomyof the donor liver. By performing MRI on a potential donor, doctors can assessany abnormality or variation in the liver itself, its vessels or its bile duct.To improve the accuracy of MRI, contrast media is used," said Myeong-JinKim, MD, one of the researchers on the study.

According to the researchers, there are different types of contrast agents.The more widely used (gadolinium-based agents) are good for imaging the liverand pathologic lesions and vessels, but not the bile duct. Other types (suchas mangafodipir trisodium) can improve imaging of the liver and bile duct, butnot the vessels. "As a result, the potential donor may need to undergotwo separate MRI examinations so that the different contrast agents can be used.Gadobenate dimeglumine can help image the liver, bile duct and vessels all atonce," said Dr. Kim.

"Our study shows that the use of this new agent may decrease the examinationcosts and time for preoperative MRI for potential living liver donors. By accurateevaluation of both vascular and biliary anatomy, adequate preoperative planningcan be ensured and it may be helpful to decrease the potential postoperativecomplications," said Dr. Kim.

The study appears in the August 2005 issue of the American Journal of Roentgenology.


Story Source:

The above story is based on materials provided by American Roentgen Ray Society. Note: Materials may be edited for content and length.


Cite This Page:

American Roentgen Ray Society. "Contrast Agent Allows Quicker, More Thorough MRI Screening Of Living Liver Donors Before Surgery." ScienceDaily. ScienceDaily, 5 August 2005. <www.sciencedaily.com/releases/2005/08/050805065223.htm>.
American Roentgen Ray Society. (2005, August 5). Contrast Agent Allows Quicker, More Thorough MRI Screening Of Living Liver Donors Before Surgery. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/08/050805065223.htm
American Roentgen Ray Society. "Contrast Agent Allows Quicker, More Thorough MRI Screening Of Living Liver Donors Before Surgery." ScienceDaily. www.sciencedaily.com/releases/2005/08/050805065223.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins